Virax Biolabs Group Ltd
VRAX0.851USD
+0.006+0.69%
Market hours （ET）Quotes delayed by 15 min
3.70MMarket Cap
--P/E TTM
More Details of Virax Biolabs Group Ltd Company
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The Company is engaged in developing a T-Cell Test technologies with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against global viral threats. Its product portfolio includes ViraxClear and Virax Immune. ViraxClear offers a range of accurate diagnostic testing kits and machines. Virax Immune is a new Covid-19 test seeking detection of T-Cell immune responses to the SARS-Cov-2 virus. Its T-Cell testing is effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Monkeypox, Hepatitis B, Malaria, Herpes and Human Papillomavirus.
Company Info
Ticker SymbolVRAX
Company nameVirax Biolabs Group Ltd
IPO dateJul 14, 2022
CEOMr. James Foster
Number of employees19
Security typeOrdinary Share
Fiscal year-endJul 14
AddressBiocity Glasgow
CityLONDON
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited Kingdom
Postal codeML1 5UH
Phone4402077887414
Websitehttps://www.viraxbiolabs.com
Ticker SymbolVRAX
IPO dateJul 14, 2022
CEOMr. James Foster
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
368.57K
+27.98%
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. James Foster
Mr. James Foster
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
368.57K
+27.98%
Mr. Evan Norton
Mr. Evan Norton
Independent Director
Independent Director
15.33K
--
Dr. Iain Miller
Dr. Iain Miller
Independent Director
Independent Director
--
--
Mr. Nelson M. Haight
Mr. Nelson M. Haight
Independent Director
Independent Director
--
--
Mr. Jason D. Davis
Mr. Jason D. Davis
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Nigel Mccracken, Ph.D.
Dr. Nigel Mccracken, Ph.D.
Chief Operating Officer, Director
Chief Operating Officer, Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Foster (James)
8.49%
Armistice Capital LLC
5.25%
Mccracken (Nigel Ph.D.)
0.54%
UBS Financial Services, Inc.
0.52%
Norton (Evan)
0.35%
Other
84.85%
Shareholders
Shareholders
Proportion
Foster (James)
8.49%
Armistice Capital LLC
5.25%
Mccracken (Nigel Ph.D.)
0.54%
UBS Financial Services, Inc.
0.52%
Norton (Evan)
0.35%
Other
84.85%
Shareholder Types
Shareholders
Proportion
Individual Investor
6.63%
Hedge Fund
5.88%
Investment Advisor
0.83%
Other
86.66%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
26
729.04K
16.79%
+148.45K
2025Q1
23
579.67K
13.35%
-10.90K
2024Q4
24
579.58K
13.35%
-22.54K
2024Q3
22
734.94K
16.93%
+329.85K
2024Q2
22
359.31K
9.40%
-99.69K
2024Q1
20
305.99K
7.33%
-151.07K
2023Q4
20
422.04K
26.02%
+96.63K
2023Q3
24
636.78K
40.92%
-179.86K
2023Q2
22
639.17K
41.06%
-174.53K
2023Q1
21
797.76K
51.31%
+134.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Foster (James)
368.57K
8.49%
+80.58K
+27.98%
Mar 31, 2025
Armistice Capital LLC
228.04K
5.25%
+228.04K
--
Sep 30, 2024
Mccracken (Nigel Ph.D.)
23.33K
0.54%
+23.33K
--
Mar 31, 2025
UBS Financial Services, Inc.
22.43K
0.52%
-15.49K
-40.85%
Mar 31, 2025
Norton (Evan)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Erez (Yair)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Haight (Nelson)
15.33K
0.35%
+15.33K
--
Mar 31, 2025
Two Sigma Investments, LP
13.63K
0.31%
+13.63K
--
Mar 31, 2025
Citadel Advisors LLC
13.54K
0.31%
+13.54K
--
Mar 31, 2025
HRT Financial LP
13.51K
0.31%
+13.51K
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Date
Type
Ratio
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
Dec 14, 2023
Merger
10<1
